Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Director/PDMR Shareholding

5 May 2015 07:01

RNS Number : 0960M
Revolymer PLC
05 May 2015
 

5 May 2015

 

Revolymer plc ("Revolymer" or "the Group")

Awards under Long Term Incentive Plan and other share awards

 

Revolymer (AIM: REVO) announces the grant of awards under the Revolymer plc Long Term Incentive Plan ("LTIP") and other share awards to its executive directors Kevin Matthews and Robin Cridland.

 

The LTIP was adopted by the board of directors of Revolymer plc (the "Board") on 29 June 2012 and its remuneration committee has approved the following grants on 30 April 2015:

· To the CEO Kevin Matthews a nil cost option over 567,568 ordinary shares

· To the CFO Robin Cridland a nil cost option over 349,550 ordinary shares.

 

The vesting period of these grants is three years and they only become exercisable if challenging performance conditions are met; namely that 50% of the grant becomes exercisable if the weighted average ordinary share price in the 180 day period ending on the third anniversary of grant is £0.75. Between weighted average ordinary share prices of £0.75 and £1.00, vesting shall be pro-rata and on a straight line basis between 50% and 100%. Below £0.75 the grants are not exercisable and lapse in full.

 

The Board also requires the executive directors to maintain minimum interests (of at least 420,000 ordinary shares for Kevin Matthews and 388,000 ordinary shares for Robin Cridland) before selling any ordinary shares that are the result of exercise, except that they may sell that number of ordinary shares that are required to satisfy any income tax and employee's national insurance liabilities arising at exercise. This requirement shall not apply on a change of control, or other transaction with substantially the same effect.

 

Also on 30 April 2015, the Board authorised the issue to Robin Cridland of 36,036 fully paid up ordinary shares in Revolymer plc ("New Shares") in recognition of his fulfilment of the role of Acting CEO during 2014 before the arrival of Kevin Matthews. Following the issue of the New Shares, Mr Cridland will hold 52,836 ordinary shares representing approximately 0.1% per cent. of the Company's issued share capital.

 

Application has been made to the London Stock Exchange for the 36,036 New Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8:00 am on 8 May 2015. Following Admission, the total number of ordinary shares in the Company will be 56,597,176 with each Ordinary Share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in ACR under the FSA's Disclosure and Transparency Rules.

 

Ends

 

For further information please contact:

Revolymer plc

+44 (0) 1244 283 500

Kevin Matthews / Rob Cridland

 

 

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Hugh Morgan / Adam James (Corporate Finance)

Charles Leigh-Pemberton (Corporate Broking)

 

 

About Revolymer

Revolymer is an AIM quoted company (registered number 08024489) that designs, develops and formulates novel polymers to improve the performance of its customers' and partners' products.

The vision for Revolymer is to build a high growth, high quality margin, specialty materials business based on proprietary polymer technology that provides responsive or smart multi-functional materials. The Board believes that the Company's technology has broad application. Revolymer aims to generate growing high quality revenue streams by either licensing its proprietary technologies or through the supply of proprietary products using an outsourced manufacturing model. Current target markets are Household Products, Personal Care and Nicotine Gum.

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEANSFEEXSEFF
Date   Source Headline
2nd Jun 20267:00 amRNSMello 2026 Presentation and Update on Trading
1st Jun 20267:00 amRNS-RProgress in Crop Production Field Trials
29th May 20267:00 amRNS-RDevelopment of Next Generation Plant-Based Paints
27th May 20267:00 amRNS-RLaunch of New Marketing Program for Detergents
14th May 20265:55 pmRNSAdjournment of AGM
6th May 20264:46 pmRNSDirector/PDMR Shareholding
27th Apr 20266:16 pmRNSTR-1
23rd Apr 20267:00 amRNSGrants of Options & PDMR dealings
24th Mar 20267:00 amRNSPreliminary Results
28th Jan 20267:00 amRNSTR-1
16th Jan 20265:29 pmRNSDirector/PDMR Shareholding
13th Jan 20267:00 amRNSFull Year Trading Update
15th Sep 20257:00 amRNSHalf Year Results
4th Sep 20257:00 amRNSNotice of Interim Results
27th Aug 20258:19 amRNSTR-1
23rd Jul 20257:00 amRNSH1 2025 Trading Update
16th Jul 20257:00 amRNS-RCroda expands agreement: sustainable odour control
1st Jul 20257:00 amRNS-RCommercial Plant-Based Product Launch
8th May 20252:20 pmRNSResult of AGM
6th May 202512:24 pmRNSTR-1
2nd May 20255:28 pmRNSNotice of AGM
1st May 20257:00 amRNSUpdate on US Tariffs
7th Apr 20257:00 amRNSGrants of Options & PDMR dealings
31st Mar 20257:00 amRNSPreliminary Results
18th Mar 20257:00 amRNSNotice of Results and Company Presentation
22nd Jan 20257:00 amRNSTrading Update
5th Nov 20247:00 amRNSTrading Update
10th Oct 20247:00 amRNSChange of Auditor
10th Sep 20247:00 amRNSHalf Year Results
2nd Sep 20247:00 amRNSNotice of Interim Results, Investor Presentation
16th Jul 20247:00 amRNSH1 2024 Trading Update
20th May 20243:03 pmRNSResult of AGM
20th May 20247:00 amRNSAGM Statement and Trading Update
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company
12th Sep 20237:00 amRNSHalf year results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.